A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
Clinical trial NCT06020144 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06020144
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-15
- Primary completion
- 2026-01-15
- Enrollment
- 459
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.